← All companies

ELVN

Enliven Therapeutics, Inc.

ELVN Nasdaq Pharmaceutical Preparations EDGAR ↗

$58.04

+4.09 +7.58%

Key statistics

from XBRL data in SEC filings

Market cap

$3.53B

Revenue (TTM)

—

Net income (TTM)

-$98.8M

EPS (TTM)

$-1.64

P/E ratio

—

Dividend yield

—

Free cash flow

-$70.5M

Cash

$132M

Total assets

$465M

Gross margin

—

52-week range

$14.79 – $59.72

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Entered a material agreement; Regulation FD disclosure Jun 12, 2026 8-K Regulation FD disclosure; Other events Jun 11, 2026 8-K Amended charter or bylaws; Shareholder vote results Jun 10, 2026 10-Q Quarter ended 2026-03-31 May 7, 2026 8-K Results of operations (earnings release) May 7, 2026 10-K Fiscal year ended 2025-12-31 Mar 3, 2026 8-K Results of operations (earnings release) Mar 3, 2026 8-K Director or officer change Jan 7, 2026 8-K Director or officer change; Regulation FD disclosure Dec 11, 2025 8-K/A Results of operations (earnings release) Nov 13, 2025 10-Q Quarter ended 2025-09-30 Nov 12, 2025 8-K Results of operations (earnings release) Nov 12, 2025 10-Q Quarter ended 2025-06-30 Aug 13, 2025 8-K Results of operations (earnings release) Aug 13, 2025 8-K Shareholder vote results Jun 25, 2025 8-K Entered a material agreement; Other events Jun 16, 2025 8-K Regulation FD disclosure; Other events Jun 13, 2025 10-Q Quarter ended 2025-03-31 May 14, 2025 8-K Results of operations (earnings release) May 14, 2025 10-K Fiscal year ended 2024-12-31 Mar 13, 2025 8-K Results of operations (earnings release) Mar 13, 2025 10-Q Quarter ended 2024-09-30 Nov 13, 2024 8-K Results of operations (earnings release) Nov 13, 2024 10-Q Quarter ended 2024-06-30 Aug 13, 2024 8-K Results of operations (earnings release) Aug 13, 2024 8-K Director or officer change; Amended charter or bylaws; Shareholder vote results Jun 18, 2024 8-K/A Director or officer change May 29, 2024 10-Q Quarter ended 2024-03-31 May 14, 2024 8-K Results of operations (earnings release) May 14, 2024 8-K Other events Apr 11, 2024 8-K Director or officer change Apr 9, 2024 8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure Mar 19, 2024 10-K Fiscal year ended 2023-12-31 Mar 14, 2024 8-K Results of operations (earnings release) Mar 14, 2024 10-Q Quarter ended 2023-09-30 Nov 9, 2023 8-K Results of operations (earnings release) Nov 9, 2023 10-Q Quarter ended 2023-06-30 Aug 10, 2023 8-K Results of operations (earnings release) Aug 10, 2023 8-K Entered a material agreement; Terminated a material agreement Jun 26, 2023 8-K Shareholder vote results; Other events Jun 23, 2023